be enough to justify preliminary development costs and initiation of product development. Later in development, it becomes necessary to know how new drug candidates are distributed and eliminated following subchronic and chronic administration in multiple species and both sexes. Finally, knowledge of toxicokinetics is used to help establish doses in long-term oncogenicity studies. Scientific, public, and regulatory pressures have recently dictated that the number of animals used in toxicology studies be closely monitored and minimized. Toxicokinetic evaluation of new drug candidates by a staggered sampling design is now routinely performed in our laboratories to maximize information obtained while reducing animal use.
INTRODUCTION
Toxicokinetics is a subdiscipline of pharmacokinetics dealing with the absorption, distribution, metabolism, and elimination ofxenobiotics at doses higher than those expected to produce therapeutic effects. Toxicokinetic evaluations are usually done with animal species used in safety assessment of drug candidates in order to aid in the understanding of toxicities observed and to assess the extent of systemic exposure. In cases where administration of relatively large quantities of drug does not produce overt toxicity, toxicokinetics may provide the only means of validating the duration and extent of exposure.
Concomitant toxicokinetics are toxicokinetic measurements made as an integrated component of animal safety studies for the assessment of systemic exposure. Concomitant toxicokinetics can be determined either directly from animals involved in nonclinical safety studies or from samples derived from satellite groups of study animals that are run in conjunction with the toxicity trials. The objectives of concomitant toxicokinetic measurements are (a) to describe the systemic exposure obtained and its relationship to toxicity observed, (b) to relate exposure to dose, (c) to provide exposure data that will aid in the determination of the margin of safety between nonclinical safety studies and human plasma concentrations achieved in clinical trials, (d) to judge interanimal variability, (e) to ascertain whether or not concentration-time profiles are dependent on the day of treatment, (f) to support the choice of species, (g) to support the nonclinical treatment regimen, and (h) to provide information that will help in the design of subsequent experiments to provide animal safety data.
DEVELOPMENT PLAN FOR TOXICOKINETIC STUDIES
Currently, no specific regulations define the scope of toxicokinetic studies to support nonclinical safety studies in the United States. However, the Inter- This document was prepared to ensure that toxicokinetic studies are carried out according to sound scientific principles and to set some expectations of what sorts of studies should be run in order to provide validation of exposure in nonclinical safety tri-
als.
A plan for regulatory submission of toxicokinetic data should be made with the specific chemical and pharmacological characteristics of the drug under development in mind (3, 5, 8) . The type of disease targeted for treatment, the route of administration, and the disposition characteristics of the drug may all affect the type of toxicokinetic studies selected.
A rational plan for generation of toxicokinetic data should be formulated on a case-by-case basis and provide for generation of sufficient data to validate systemic exposure and account for interpretation of similarities and differences in toxicity across species, dose groups, and sexes. In addition, when concomitant toxicokinetic studies are run in support of drug safety, they should be run in accordance with standards set for Good Laboratory Practices (4).
In general, toxicokinetic studies should be designed to determine in what manner plasma concentrations change (e.g., linear, proportional) following increases in dose. An elimination half-life (T,,,J should be measured and calculated to aid the toxicologist in determining the appropriate frequency or mode of dose administration. The behavior of test article in each sex should be determined and the data should be closely scrutinized to determine whether or not the disposition of drug is similar in both sexes. Because a variety of species are commonly used in drug development, toxicokinetic measurements should be made in all species that are used in support of drug safety. Bioanalytical measurements in toxicokinetic studies should be de-signed to discriminate between parent drug and principle metabolic conversion products in order to evaluate the potential for accumulation of some drug product (9) . These factors taken together with any other unique characteristics of the drug should be evaluated when finalizing a toxicokinetic plan in support of product registration. TIMING OF ToxicoKiNETic STUDIES Toxicology serves a variety of customers who need toxicokinetic information (Fig. 1 ). Biochemical or exploratory toxicology groups must work closely with chemists and pharmacologists from discovery research to relate plasma concentrations of drug to pharmacologic or toxicologic effects. Drug metabolism groups work with toxicologists to provide measurements of parent drug and principle bioconversion products to answer questions relative to bioavailability and extent of exposure. Changes in product formulation may affect the systemic availability of drug products, so that product development groups must work closely with toxicologists to assess the impact of changes in formulation. Clinicians and pharmacokineticists use toxicokinetic data to help set the intended clinical dose and to design pharmacokinetic studies to validate human safety and efficacy trials.
There also exists a variety of customers within toxicology for these data. Toxicologic pathologists may use toxicokinetic data to relate lesions to exposure. Toxicology study directors use toxicokinetic data to modify dose administration and to aid in species selection during the course of nonclinical safety studies. Reproduction and developmental toxicologists use toxicokinetic data to aid in dose selection for reproduction and teratology studies. When outliers are found in the observed toxicity among animals, toxicokinetic data may help relate resultant toxicity to individual animal differences in exposure.
Toxicokinetic data are generated throughout toxicity testing, and the plan for nonclinical animal studies should be modified as data are collected and evaluated (3, 6) . A typical toxicology development plan for therapeutic candidate development is depicted in Fig. 2 . Toxicokinetics are generated in nearly every stage of compound development, from the earliest 7-14-day pilot studies to the longer term chronic studies of up to (Fig. 3 ). Compression of development timelines has necessitated initiation of bioanalytical studies at the earliest possible time in compound development in order to supply toxicokinetic data in a timely fashion.
REQUIREMENTS FOR EFFECTIVE TOXICOKINETIC TRIALS
One requirement of early and effective implementation of toxicokinetics into the interpretation and modification of subsequent safety studies is timely development of an appropriate bioanalytical method. The bioanalytical method should have appropriate selectivity and sensitivity to measure disposition kinetics of parent compound and principle metabolite(s) in the appropriate biological matrix (9) . The method should permit evaluation of the extent and duration of exposure. The method should also be able to determine necessary concentrations in the appropriate biological matrix with realistic sample volumes. The bioanalytical method is the cornerstone of effective and timely use of toxicokinetics in nonclinical safety studies, and early meth-ods may need to be modified as compounds move through development. Early bioanalytical methods should have sufficient selectivity to discriminate parent compound from metabolites. Because the early studies are often done at very high doses, it usually is not essential to optimize methods for maximal sensitivity in early trials. As compounds move through nonclinical toxicity trials and into clinical trials, a sensitive and selective method must be validated for increasingly low doses of test article. Recent advances in analytical instrumentation such as the broad-scale use of atmospheric pressure chemical ionization mass spectrometry in commercially available high-pressure liquid chromatography equipment have facilitated both the early-and late-phase requirements of bioanalytical methodology (1, 2).
Pharmacokinetic and toxicokinetic measurements are often made in individual animals or in satellite groups of animals used in a toxicity trial. The goals of these early determinations are to identify parameters of importance for interpreting exposure data such as the maximum plasma concentration achieved (C,a_,,), the time to maximum plasma concentration (T max), the area under the concentration-time curve (AUC), clearance (CL), the volume of distribution at steady state (Vss), and the elimination half-life (T,,2 ) (7). These parameters de- fine the basis for the toxicokinetic comparisons within and among species in toxicity trials.
With few exceptions, blood volume collections
should not exceed 10% of the total blood volume in any individual animal during the course of a concomitant toxicokinetic trial. In single-dose studies, samples should be drawn over a period of 4-5 halflives in order to obtain a good estimate of AUC. In multiple-dose studies, toxicokinetic determinations should be made on day I and at some frequency during the course of the toxicity trial to determine whether or not differences in plasma kinetics occur as a result of multiple doses of test compounds.
REPLICATE VS STAGGERED EXPERIMENTAL DESIGNS IN TOXICOKINETIC STUDIES
Replicate designs for sampling blood, plasma, and tissues from laboratory animals are robust and employed in many different types of studies used to support drug safety. In replicate designs, groups of animals are sampled at similar preset timepoints and measured values are averaged to provide an estimate of drug exposure. Typically, 3 or more animals are used to provide data for each timepoint, and mean data with standard deviation or standard error bars are graphed to provide exposure curves for test groups. The number of timepoints (typically 4-8) when samples are taken is dependent on the kinetics of the drug under evaluation. Frequently, destructive sampling is used in this design, and animals are euthanized following, or as a result of, sample collection. Replicate designs are especially sensitive to sampling time schedules, and care should be taken when scheduling sample timepoints.
In staggered designs, more sampling times are scheduled during a given dosing interval than in replicate designs. Typically, 10-12 staggered timepoints are used to provide concentration-time curves, and individual animal data are used for toxicokinetic calculations. In staggered designs with rodents, the sampling may or may not be destructive, and the use of satellite animals can be reduced with proper nondestructive techniques such as orbital bleeds from toxicology study animals. Staggered designs are less sensitive to sampling time schedules because more timepoints are typically taken, but staggered designs are more sensitive to interanimal variability.
Selection of staggered or replicate sampling for a compound under development is dependent on variability expected among animals. Sampling in study animals reduces animal use and permits direct correlation of plasma and tissue concentrations of drug to toxicologic findings. Care should be taken to ensure that sampling does not occur with such frequency to alter the outcome of a toxicity trial but with adequate frequency to estimate exposure. Specific sampling times should be set based on previous experience with the drug in question.
STRATEGY FOR SAMPLING IN TOXICITY TRIALS
Even though it is recommended that toxicokinetic trials be developed on a case-by-case basis for new drug candidates, it is generally useful to have a template of expected procedures to aid toxicology study directors in formulating a development plan. A general plan should suggest appropriate general sampling schedules and eliminate unnecessary use of laboratory animals. A general plan should also identify the goals of toxicokinetic measurements at each stage of development and eliminate redundancy in sampling whenever possible. We propose the following development plan as being generally useful in our laboratories, with the caveat that exceptions to this plan are recognized when appropriate.
Staggered sampling designs have been adopted by our laboratories to satisfy some of the aforementioned goals. Staggered designs are suggested early in compound development, and a sampling scheme for rodent presubchronic studies is shown in Table  I . In these presubchronic studies, relatively large samples are taken from individual animals to allow sufficient material for analysis by bioanalytical chemists. In this stage of development, the bioanalytical method is usually in a state of infancy, and the samples obtained in this study are used to help validate the method and ensure that no bioconversion products or endogenous contaminates will preclude the use of the assay for the longer term repeated-dose studies. The doses in these early studies are usually the highest that animals will be exposed to during the course of drug development, and the data obtained are especially useful in establishing a dose-response-plasma concentration relationship throughout the dosing range.
The proposed strategy for rodent subchronic studies also involves a staggered sampling strategy (Table I). The intent of this phase of toxicokinetic investigation is to thoroughly examine the toxicokinetics in males and to document exposure and plasma concentrations achieved in females. The proposed staggered sampling design provides for the use of fewer study animals than traditional replicate designs with a total of 144 animals used in the proposed staggered sampling design vs 252 animals from a traditional replicate design (Fig. 4 ). Staggered sam- pling in the rodent subchronic studies also allows a wider range of timepoints due to the use of single animals per timepoint for toxicokinetic measurements.
In studies of 6-mo duration, additional data are gathered in male animals and complete toxicokinetic measurements are determined in females. The chronic rodent studies are planned with data obtained from the pilot and subchronic studies and timepoints are set accordingly. Usually, by this stage of development, a bioanalytical method has been identified and thoroughly investigated, and the sensitivity of the assay has been enhanced due to the need for greater sensitivity in analysis of samples from anticipated human clinical trials. These improvements in sensitivity of bioanalytical methods may make it possible to directly sample rodents from toxicity trials without the need for separate satellite groups. When toxicokinetics are critical to interpretation of study outcome, animal studies should not be initiated until a validated analytical method is in place.
Staggered sampling in dogs is not often used in our laboratories because relatively large volumes of plasma may be taken with some frequency directly from study animals (Table II) . In pilot dog studies, animals are sampled at 7 or 8 timepoints per dose to gain a rough estimate of dose proportionality, T,,,* T~a., Cmax and to set doses for the dog subchronic studies. Because it is preferable to treat all the study animals in a similar manner to normalize the impact of sample collection, blood collections are made from all study animals in our dog studies. The need to normalize the impact of sampling is also a reason for our decision to use replicate vs staggered sampling in dogs as replicate designs are easier to control in these types of studies. Every effort is made to minimize redundant collection of kinetic data and to build toxicokinetic studies from data obtained during the course of development.
Typical primate study designs are shown in Table  III . A mixture of replicate and staggered sampling designs has been used for monkey studies in our laboratories. Because primates are generally smaller in size than dogs, this mixture of staggered and replicate design provides the opportunity to make a number of observations over a large sampling interval. In this mixed design. indivdual animals may be sampled at 4-6 timepoints and merged with data obtained from other study animals into a composite kinetic curve. This sort of design blends the best of both the staggered and replicate designs. 
CONCLUSIONS
Toxicokinetic measurements, whether made directly in animals used in nonclinical safety studies or in separate groups of satellite animals, provide important information concerning the extent and duration of exposure. The most effective development plans will apply necessary toxicokinetic measurements on a case-by-case basis and will design each sequential study with careful consideration of information obtained from previous studies. For this strategy to be effective, appropriate bioanalytical methods must be developed early and methods should be in place from the time of the earliest pilot studies.
Modem staggered sampling designs provide optimum breadth in sampling schemes and may provide successful alternatives to traditional replicate study designs. Staggered sampling designs can reduce the number of animals required to generate toxicokinetic data through reduced requirements for animal numbers in trials and by nondestructive sampling directly from rodents used in nonclinical safety trials. The toxicokinetic sampling scheme described in this report has been successfully used for more than a year in our laboratories and provides a template for study directors to work from and modify as needed throughout the course of toxicity assessment.
